Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Debt (2020 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Total Debt for 8 consecutive years, with $61.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt rose 4.07% year-over-year to $61.9 million, compared with a TTM value of $61.9 million through Dec 2025, up 4.07%, and an annual FY2025 reading of $61.9 million, up 4.07% over the prior year.
  • Total Debt was $61.9 million for Q4 2025 at Zevra Therapeutics, up from $61.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $61.9 million in Q4 2025 and bottomed at $781000.0 in Q1 2021.
  • Average Total Debt over 5 years is $37.2 million, with a median of $42.8 million recorded in 2023.
  • The sharpest move saw Total Debt dropped 0.71% in 2023, then soared 1061.13% in 2024.
  • Year by year, Total Debt stood at $781000.0 in 2021, then skyrocketed by 1538.92% to $12.8 million in 2022, then surged by 234.11% to $42.8 million in 2023, then soared by 39.14% to $59.5 million in 2024, then grew by 4.07% to $61.9 million in 2025.
  • Business Quant data shows Total Debt for ZVRA at $61.9 million in Q4 2025, $61.3 million in Q3 2025, and $60.7 million in Q2 2025.